Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance.

MLA

Gil-Núñez, A., et al. “Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Secondary Prevention of Vascular Events in Patients with Stroke: Consensus Document and Practice Guidance.” Neurologia, vol. 37, no. 2, Mar. 2022, pp. 136–50. EBSCOhost, https://doi.org/10.1016/j.nrleng.2020.11.014.

APA

Gil-Núñez, A., Masjuan, J., Montaner, J., Castellanos, M., Segura, T., Cardona, P., Tembl, J. I., Purroy, F., Arenillas, J., & Palacio, E. (2022). Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance. Neurologia, 37(2), 136–150. https://doi.org/10.1016/j.nrleng.2020.11.014

Chicago

Gil-Núñez, A, J Masjuan, J Montaner, M Castellanos, T Segura, P Cardona, J I Tembl, F Purroy, J Arenillas, and E Palacio. 2022. “Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Secondary Prevention of Vascular Events in Patients with Stroke: Consensus Document and Practice Guidance.” Neurologia 37 (2): 136–50. doi:10.1016/j.nrleng.2020.11.014.